Avadel Phrmctcls ADR (AVDL)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Gregory J. Divis
Employees:
70
BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN, IRELAND 15
636-449-1830

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.

Data derived from most recent annual or quarterly report
Market Cap 1.172 Billion Shares Outstanding89.368 Million Avg 30-day Volume 729.187 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.41
Price to Revenue108.1657 Debt to Equity0.1923 EBITDA-128.916 Million
Price to Book Value8.3607 Operating Margin-1597.9671 Enterprise Value788.55 Million
Current Ratio3.187 EPS Growth0.031 Quick Ratio2.949
1 Yr BETA 0.9031 52-week High/Low 16.85 / 5.92 Profit Margin-1867.6851
Operating Cash Flow Growth-49.5894 Free Cash Flow to Firm (FCFF) TTM -56.03 Million Free Cash Flow to Equity (FCFE) TTM-64.68 Million
Altman Z-Score-0.4679
View SEC Filings from AVDL instead.

View recent insider trading info

Avadel Phrmctcls ADR YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding AVDL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AVDL

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-09-01 by PALCZUK LINDA
  • 4: filed on 2023-09-01 by GLASS GEOFFREY MICHAEL
  • 4: filed on 2023-08-15 by MCCAMISH MARK ANTHONY
  • 4: filed on 2023-08-14 by MCHUGH THOMAS S
  • 4: filed on 2023-08-11 by GLASS GEOFFREY MICHAEL
  • 4: filed on 2023-08-10 by DIVIS GREGORY J
  • 4: filed on 2023-08-03 by ENDE ERIC J
  • 4: filed on 2023-08-03 by GLASS GEOFFREY MICHAEL
  • 4: filed on 2023-08-03 by MCCAMISH MARK ANTHONY
  • 4: filed on 2023-08-03 by PALCZUK LINDA

    • Events (8k)

  • 8-K: filed on 2023-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-03:
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
  • 8-K: filed on 2023-08-03:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-05:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-31:
    Item 8.01: Other Events
  • 8-K: filed on 2023-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-01:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-05:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-03:
    Item 8.01: Other Events

    • Proposed Sales (Form 144)

  • 144: filed on 2023-08-11:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GLASS GEOFFREY MICHAEL

    • Director
    		 0 2023-09-01 3

    PALCZUK LINDA

    • Director
    		 0 2023-09-01 5

    MCHUGH THOMAS S CHIEF FINANCIAL OFFICER

    • Officer
    		 78,500 2023-08-14 2

    MCCAMISH MARK ANTHONY

    • Director
    		 142,025 2023-08-11 2

    DIVIS GREGORY J CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 159,100 2023-08-10 2

    THORNTON PETER J.

    • Director
    		 0 2023-08-01 1

    ENDE ERIC J

    • Director
    		 0 2023-08-01 2

    KIM RICHARD J CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2023-06-05 1

    WILLIAMSON DOUGLAS J CHIEF MEDICAL OFFICER

    • Officer
    		 0 2022-02-14 0

    HATTEN SANDRA L SEE REMARKS

    • Officer
    		 59,165 2019-12-12 0

    VAUGHN JASON SR. VP, TECHNICAL OPERATIONS

    • Officer
    		 0 2019-11-05 0

    KOTLER KEVIN

    BROADFIN CAPITAL, LLC

    BROADFIN HEALTHCARE MASTER FUND LTD

    • Director
    		 3,130,573 2019-08-07 0

    GUSKY DAVID P SEE REMARKS

    • Officer
    		 No longer subject to file 2019-06-30 0

    STAPLETON CRAIG R

    • Director
    		 No longer subject to file 2019-05-09 0

    DUBOW JORDAN CHIEF MEDICAL OFFICER

    • Officer
    		 0 2019-04-29 0

    KANAN MICHAEL F SEE REMARKS

    • Officer
    		 50,538 2019-03-07 0

    THOMPSON PHILLANDAS T. SEE REMARKS

    • Officer
    		 113,671 2019-03-07 0

    ANDERSON MICHAEL S SEE REMARKS

    • Officer
    • Director
    		 No longer subject to file 2018-12-28 0

    VAN ASSCHE BENOIT

    • SEE REMARKS
    		 No longer subject to file 2018-07-18 0

    FILDES FRANCIS

    • SEE REMARKS
    		 No longer subject to file 2018-07-18 0

    NAVARRE CHRISTOPHE

    • SEE REMARKS
    		 No longer subject to file 2018-07-18 0

    FLYNN JAMES E

    DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

    DEERFIELD PRIVATE DESIGN FUND II, L.P.

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD MGMT L.P.

    DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.

    BREAKING STICK HOLDINGS, LLC

    • 10% Owner
    • *POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP*POSSIBLE MEMBER OF 10% GROUP
    		 No longer subject to file 2018-06-25 0

    D'SILVA DHIREN VP IRISH & EUROPEAN OPERATIONS

    • Officer
    		 No longer subject to file 2018-02-07 0

    MACKE SCOTT A.

    • SEE REMARKS
    		 No longer subject to file 2017-10-10 0

    DAVIS GREGORY J.

    • SEE REMARKS
    		 No longer subject to file 2017-10-10 0

    SULLIVAN STEPHEN G.

    • SEE REMARKS
    		 No longer subject to file 2017-10-10 0

    MONTEITH DAVID

    • SEE REMARKS
    		 No longer subject to file 2017-10-10 0

    ELROD MARCUS W

    • SEE REMARKS
    		 No longer subject to file 2017-10-10 0

    CERUTTI GUILLAUME

    • SEE REMARKS
    		 No longer subject to file 2017-06-28 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-05 19:15:04 UTC 4.6202 0.6998 1500000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-05 18:45:04 UTC 4.6202 0.6998 1500000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-05 18:15:03 UTC 4.6202 0.6998 1500000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-05 17:45:04 UTC 4.6202 0.6998 1500000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-05 17:15:04 UTC 4.6291 0.6909 1500000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-05 16:45:04 UTC 4.6291 0.6909 1500000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-05 16:15:04 UTC 4.6291 0.6909 1500000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-05 15:45:04 UTC 4.6893 0.6307 1500000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-05 15:15:05 UTC 4.6893 0.6307 1500000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-05 14:45:03 UTC 4.6819 0.6381 1500000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-05 14:15:04 UTC 4.6819 0.6381 1500000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-05 13:45:04 UTC 4.7447 0.5753 1400000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-05 13:15:04 UTC 4.7447 0.5753 1400000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-05 12:45:05 UTC 4.7447 0.5753 1400000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-04 22:15:04 UTC 4.7407 0.5793 1400000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-04 21:45:03 UTC 4.7407 0.5793 1400000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-04 21:15:03 UTC 4.7407 0.5793 1400000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-04 20:45:04 UTC 4.7407 0.5793 1400000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-04 20:15:05 UTC 4.7407 0.5793 1400000
    AVADEL PHARMACEUTICALS-ADR AVDL 2023-12-04 19:45:03 UTC 4.7407 0.5793 1400000

    Current Active Short Positions

    Get more info on our International short position coverage here

    Holder Issuer Net Short Position Position Date Origin
    Franklin Alternative Strategies Funds- K2 Alternative Strategies Fund AVDL -42988.0 shares, $-580767.88 2023-08-31 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund AVDL -200.0 shares, $-2060.0 2023-09-30 N-PORT

    Short Position History (International Only)

    Holder Net Short Position Position Date Origin
    Bronte Capital Management Pty Ltd Avadel Pharmaceuticals plc 0.58% 2022-07-19 GERMANY
    Bronte Capital Management Pty Ltd Avadel Pharmaceuticals plc 0.66% 2022-07-27 GERMANY
    Bronte Capital Management Pty Ltd Avadel Pharmaceuticals plc 0.58% 2022-08-12 GERMANY
    Bronte Capital Management Pty Ltd Avadel Pharmaceuticals plc 0.65% 2022-09-22 GERMANY
    Bronte Capital Management Pty Ltd Avadel Pharmaceuticals plc 0.59% 2022-12-07 GERMANY
    Bronte Capital Management Pty Ltd Avadel Pharmaceuticals plc 0.65% 2023-01-19 GERMANY
    Bronte Capital Management Pty Ltd Avadel Pharmaceuticals plc 0.58% 2023-03-01 GERMANY
    LINDEN ADVISORS LP Avadel Pharmaceuticals plc 3.94% 2018-06-01 GERMANY
    LINDEN ADVISORS LP Avadel Pharmaceuticals plc 3.81% 2018-06-05 GERMANY
    LINDEN ADVISORS LP Avadel Pharmaceuticals plc 3.57% 2018-06-08 GERMANY
    LINDEN ADVISORS LP Avadel Pharmaceuticals plc 1.34% 2018-06-26 GERMANY
    LINDEN ADVISORS LP Avadel Pharmaceuticals plc 0.99% 2018-08-22 GERMANY
    LINDEN ADVISORS LP Avadel Pharmaceuticals plc 0.63% 2018-08-30 GERMANY

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments